Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04007094 · ClinicalTrials.gov registry record · NA
Single-Armed Use of ViviGen Cellular Bone Matrix in Patients Undergoing Posterolateral Lumbar Surgery
A NA study, sponsored by Ohio State University.
- Terminated
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT04007094 is a NA study that was terminated before completion, run by Ohio State University. The registered enrollment target is 21 participants.
The verdict
NCT04007094, a NA study, was terminated before completion, sponsored by Ohio State University.
- TERMINATED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a prospective, single-arm post market study of patients to assess fusion in one or multiple continuous levels of the lumbosacral spine (L1-S1) using ViviGen Cellular Bone Matrix. All subjects will be followed out to 24 months for final assessment.
Interventions
- OTHER ViviGen Cellular Bone Matrix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2019-02-12 |
| Est. Completion | 2022-01-21 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04007094
The ClinicalTrials.gov registry entry for NCT04007094 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ViviGen Cellular Bone Matrix is the first listed.
NCT04007094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04007094 about?
NCT04007094 is a clinical study titled "Single-Armed Use of ViviGen Cellular Bone Matrix in Patients Undergoing Posterolateral Lumbar Surgery". This is a prospective, single-arm post market study of patients to assess fusion in one or multiple continuous levels of the lumbosacral spine (L1-S1) using ViviGen Cellular Bone Matrix. All subjects will be followed out to 24 months for final assessment.
What is the current status of trial NCT04007094?
This trial is currently terminated. It is a NA study. The enrollment target is 21 participants. The study started on 2019-02-12. Estimated completion is 2022-01-21.
What interventions are being tested in trial NCT04007094?
The interventions under investigation include: ViviGen Cellular Bone Matrix (OTHER).
Who is sponsoring clinical trial NCT04007094?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.